6533b830fe1ef96bd12968e3

RESEARCH PRODUCT

The ocular penetration of oral sparfloxacin in humans

Herve LecoeurA. KazmierczakAlain M. BronAndré PechinotDaniela A. SchottGuy A. GuyonnetCatherine P. Creuzot Garcher

subject

Malemedicine.drug_classmedicine.medical_treatment[SDV]Life Sciences [q-bio]AntibioticsAdministration OralCataract ExtractionMicrobial Sensitivity TestsQuinolonesAqueous HumorPharmacokineticsAnti-Infective AgentsOral administrationVitrectomyMedicineIngestionHumansChromatography High Pressure LiquidAntibacterial agentAgedAged 80 and overChemotherapybusiness.industryCataract surgeryMiddle Agedeye diseases[SDV] Life Sciences [q-bio]Vitreous BodyOphthalmologySparfloxacinAnesthesiaFemalesense organsbusinessmedicine.drugFluoroquinolones

description

The penetration of sparfloxacin into the aqueous humor after oral administration was studied in 28 patients undergoing cataract surgery. Each patient received a single, oral dose of 400 mg of sparfloxacin. In eight other patients scheduled to undergo vitreal surgery, multiple daily oral doses were administered for a total amount of 1,000 mg. The aqueous levels were (mean +/- SEM) 0.127 +/- 0.036 microgram/ml to 0.404 +/- 0.159 microgram/ml from two to 24 hours after ingestion. In the vitreous, the mean drug level was 0.840 microgram/ml (range, 0.480 to 2.060 microgram/ml), from 4.3 to 8.0 hours after the most recent oral dose. Blood samples obtained at the same time as vitreous and aqueous taps were assayed by high-performance liquid chromatography. These data demonstrate that therapeutic levels of sparfloxacin may be achieved in noninflamed, noninfected eyes undergoing cataract or vitreous surgery.

yearjournalcountryeditionlanguage
1994-01-01
https://hal.inrae.fr/hal-02712648